How Often Should A Man Get His Prostate Checked?

Prostate cancer is the most common cancer diagnosis in American men, and catching it early makes a real difference in outcomes. How often a man should get his prostate checked depends on his age, PSA results, and personal risk factors, but for most men at average risk, the standard recommendation is every 2 to 4 years between ages 50 and 69.

Screening intervals can run anywhere from once a year – when PSA is elevated or climbing – to once every 5 years when PSA stays very low. The right schedule isn’t one-size-fits-all; it’s something you and your doctor work out together. This article covers what the guidelines say, what each test involves, and how your personal risk profile should shape that conversation.

How Often Should You Get Your Prostate Checked?

For average-risk men, the current standard calls for screening every 2 to 4 years between ages 50 and 69, per age-specific guidelines from Johns Hopkins Medicine. The PSA (prostate-specific antigen) blood test is the primary tool, often paired with a digital rectal exam (DRE). Frequency shifts with results: a PSA below 2.5 ng/mL typically means testing every 2 years, while a reading at or above 2.5 ng/mL generally moves you to annual checks. Black men and those with a family history of prostate cancer should start earlier and screen more consistently.

A thorough guide to prostate cancer screening covers the full range of screening options, and you can also find a detailed breakdown of how often a man should get his prostate checked with age-specific advice. Understanding PSA testing’s usefulness and limits helps set realistic expectations before you walk into that appointment.

Research from a 2025 systematic review found a 20 to 31% prostate cancer mortality reduction PSA screening among men aged 55 to 69, which is why consistent interval-based screening remains the clinical recommendation despite ongoing debate.

Screening recommendations by age and risk

Risk Profile	Starting Age	Typical Interval
Average risk	50	Every 2 to 4 years
Higher risk (Black ancestry or family history)	40 to 45	Annually or every 1 to 2 years
PSA < 2.5 ng/mL	Any age in range	Every 2 years
PSA ≥ 2.5 ng/mL	Any age in range	Annually
Age 75+, PSA < 3 ng/mL	N/A	Consider stopping

Why recommendations differ for different men

No two prostates age identically. PSA trajectory, family history, ethnicity, and overall health all shift the equation. A man with a stable PSA of 1.1 ng/mL at 58 needs checking far less urgently than one whose PSA jumped from 2.8 to 4.2 ng/mL in two years. The trend matters as much as the number.

What a Prostate Screening Actually Involves

The PSA blood test and the digital rectal exam (DRE) are the two main screening tools in common use. Used together, they give your doctor a clearer picture than either test can provide on its own, per the Medscape clinical guidelines overview. Neither is perfect. That’s exactly why the conversation with your doctor matters so much.

The PSA blood test

PSA is a protein produced by prostate tissue. A blood draw measures how much of it is circulating, and higher levels can signal cancer, though not always. The commonly cited ranges are:

• Under 4 ng/mL: Generally considered normal, though age affects interpretation
• 4 to 10 ng/mL: A gray zone; cancer is found in roughly 25% of biopsies here
• Over 10 ng/mL: More concerning; cancer probability rises above 50%

Knowing what normal PSA looks like by age puts your number in context, a PSA of 3.5 means something quite different at 50 than it does at 70. The test carries real limitations; factors that can skew PSA results include an enlarged prostate (BPH), prostatitis, recent sexual activity, and even vigorous cycling. False positives generate unnecessary anxiety and sometimes push men toward biopsies they don’t need.

The digital rectal exam

The DRE involves a clinician inserting a gloved, lubricated finger into the rectum to feel the back surface of the prostate for lumps, hardness, or asymmetry. It’s quick, usually under a minute. Uncomfortable? Briefly. Worth doing? Usually yes, because a small number of prostate cancers cause PSA changes that are subtle but produce a palpable abnormality.

A detailed guide to what a digital rectal exam involves walks through exactly what to expect during the procedure. PSA is generally more sensitive than DRE alone, but the physical exam still catches cancers that PSA can miss. That’s why most urologists rely on both, particularly for men at higher risk.

Are There Newer Screening Methods Beyond PSA and DRE?

PSA and DRE remain the standard first-line tools recommended by major guidelines. But several adjunct tests now exist to help when PSA results are ambiguous:

• Multiparametric MRI (mpMRI): Reduces unnecessary biopsies by improving specificity. The 2026 AUA/SUO guideline strongly integrates mpMRI into the post-PSA diagnostic pathway.
• 4Kscore and PHI (Prostate Health Index): Blood-based tests that refine risk assessment beyond total PSA alone, reducing low-risk biopsy referrals.
• SelectMDx: A urine-based biomarker test used as an adjunct to PSA for risk stratification.

The Facing Our Risk of Cancer Empowered resource outlines available options for men weighing their individual risk profile. None of these newer tools has displaced PSA as the starting point. They come into play after an elevated PSA result, helping determine whether a biopsy is truly warranted. That distinction is significant, mpMRI has been shown to cut overdetection of clinically insignificant cancer by nearly 50%. Access and cost still vary considerably, though.

Research tracking PSA testing trends across different countries highlights that adoption of adjunct tools remains uneven, even in high-income health systems.

Why the Guidelines Keep Changing

The tension here is straightforward. PSA screening saves lives, but it also flags slow-growing cancers that would never have caused any harm, and treating those men carries real risk of incontinence and erectile dysfunction as a treatment side effect of prostate cancer therapy. Getting the interval right means capturing the mortality benefit without piling on unnecessary procedures.

The AUA/SUO 2026 Early Detection of Prostate Cancer guideline is the current US standard, built on years of weighing exactly this tradeoff. The US Preventive Services Task Force takes a parallel position, recommending shared decision-making for men aged 55 to 69. Both bodies agree on one thing: the decision belongs to the individual, informed by his own risk profile.

The PSA test controversy

The debate crested after two large trials – ERSPC (European) and PLCO (American) – reached opposite conclusions about whether PSA screening actually reduced deaths. The ERSPC showed a clear mortality reduction; PLCO did not, though its screening arm was later found to be contaminated by high rates of PSA testing in the supposed “control” group. Most experts now lean toward the ERSPC result, but the uncertainty drove a decade of cautious guidance.

Overdiagnosis and overtreatment concerns

The American Cancer Society’s recommendations stress shared decision-making in part because of overdiagnosis risk. Studies put the 20 to 50% overdiagnosis risk from PSA-only screening at a wide range depending on strategy, meaning a large share of detected cancers would never have caused symptoms or death. That’s why active surveillance – monitoring rather than immediate treatment – has become the standard approach for low-risk cancers caught through screening.

When You Should Start Getting Screened

The right starting age depends heavily on your personal risk. A 2025 analysis tracking prostate cancer stage-specific incidence trends reinforces that late-stage diagnoses are rising, particularly in younger men, which makes the timing of that first baseline PSA more consequential than it used to be.

Men unlikely to benefit from screening are those with less than a 10-year life expectancy minimum for screening benefit, which is why screening recommendations typically advise tapering or stopping in older men with other serious health conditions.

A practical look at when to get a prostate exam by age shows that current guidelines break clearly along average-risk and higher-risk lines. Understanding what happens to your prostate as you age also explains why it becomes a screening priority in the first place. It’s the only gland in the body that keeps growing throughout a man’s life.

If you’re at average risk

Average-risk men should start the shared decision-making conversation at age 50, with screening beginning shortly after. A PSA below 2.5 ng/mL supports retesting every 2 years; a reading below 1.0 ng/mL at age 60 may justify spacing checks up to 5 years apart. Five years is the maximum recommended interval for average-risk men with very low PSA, not an indefinite pause. Men over 75 with PSA under 3 ng/mL can reasonably stop routine screening.

If you’re at higher risk

Black men and men with a first-degree relative diagnosed with prostate cancer before age 65 should start screening at 40 to 45. Modelling data suggests prostate cancer develops 3 to 9 years earlier in Black men than in their peers, and earlier baseline testing could cut prostate cancer mortality in this group by roughly 30%, per a 2024 analysis published in NEJM Evidence. Annual screening is well worth considering for high-risk men, especially when PSA is trending upward.

Information on prostate cancer risk factors in younger men is worth reviewing if you have family history concerns before age 45.

What to Discuss With Your Doctor Before Screening

Screening isn’t something to do passively. Your doctor weighs PSA history, family history, ethnicity, current health, and likely life expectancy together. No formula replaces that conversation. A 2022 international comparison of PSA screening guidelines found meaningful variation between countries, which underlines that these decisions involve genuine clinical judgment, not just a single number.

Knowing the warning signs of prostate cancer before that appointment puts you in a stronger position to describe what you’ve noticed. Understanding the full picture of prostate cancer causes, symptoms, and treatments also helps you ask sharper questions.

Questions to ask about the benefits and risks

Before screening, ask your doctor:

• What would a biopsy actually involve if my PSA comes back elevated?
• How has my PSA trended over the past few years?
• Given my age and health, what’s your recommendation on interval?
• Would any adjunct test (4Kscore, mpMRI) be useful if PSA is borderline?

Making a shared decision about screening

Shared decision-making means you understand the potential benefits (a real reduction in dying from prostate cancer) and the potential harms, including false positives, biopsy complications, and treatment side effects for cancers that may never have progressed. Your values matter here. Some men prioritize early detection above all; others weigh the intervention risk heavily. Both are reasonable.

What Happens if Your Screening Results Come Back Abnormal

An abnormal result doesn’t mean cancer. It means more information is needed. PSA between 4 and 10 ng/mL places you in a gray zone where cancer is found in roughly one in four biopsies, which also means three in four biopsies in that range come back negative. A PSA above 10 ng/mL raises the probability meaningfully.

A 2025 evidence review on PSA retesting intervals notes that current guidelines lack direct clinical trial evidence for specific retesting schedules, reinforcing why individual clinical judgment matters at every step.

Elevated PSA levels and what they might mean

PSA rises for reasons that have nothing to do with cancer. BPH is a common culprit, understanding PSA levels in BPH helps put a borderline result in perspective. Prostatitis, recent sexual activity, and even a urinary tract infection can temporarily push PSA higher. Your doctor may retest in 4 to 6 weeks before taking any action on a single elevated reading.

Next steps after an abnormal result

A sustained elevation or a concerning DRE finding typically leads to an mpMRI first, followed by a targeted or systematic biopsy if imaging supports it. The biopsy produces a Gleason score, which grades the cancer’s aggressiveness and steers treatment decisions. Each step from an abnormal PSA to an actual diagnosis sharpens the picture a little more.

Prostate Health Between Screenings

Screening schedules are one part of the equation. What you do between appointments also matters. A growing body of evidence links lifestyle factors (diet, exercise, weight, and smoking) to prostate cancer risk and progression. Research tracking global prostate cancer burden from 1990 to 2021 shows that modifiable risk factors account for a meaningful share of incidence, which is good news because it means daily choices carry real weight.

Lifestyle factors that support prostate health

Practical steps worth taking include eating more vegetables – especially tomatoes, cruciferous vegetables, and legumes – cutting back on red meat, maintaining a regular exercise routine for prostate health, and keeping weight in a healthy range. Evidence-backed approaches to prostate cancer prevention lays these out clearly. For men dealing with prostatitis alongside their screening schedule, natural approaches to prostatitis management may support urinary comfort between appointments.

Some men find it useful to pair proactive lifestyle choices with a science-backed supplement formulated for prostate and urinary health. 

When to see a doctor for symptoms

Don’t wait for your next scheduled appointment if you develop urinary symptoms like frequent urination, urgency, or difficulty starting flow. Symptoms call for earlier medical review regardless of where you are in your screening schedule. Blood in urine or semen, new pelvic pain, or bone pain in the hips or lower back are red flags that need prompt attention. Don’t sit on those until your next annual check.

Frequently Asked Questions About Prostate Screening

Does a high PSA always mean prostate cancer?

No. PSA can rise due to BPH, prostatitis, infection, or even recent physical activity. A single elevated result typically leads to a repeat test and further evaluation before any biopsy is considered.

Can prostatitis affect my PSA screening results?

Yes, it can, and this is a point that’s commonly missed. Inflammation from acute prostatitis or chronic prostatitis can significantly raise PSA, producing false-positive screening results. Knowing the warning symptoms of prostatitis before your test helps your doctor interpret any elevation in the right context.

How common is prostate cancer actually?

Very common. A 2025 report from the American Cancer Society estimated 313,780 new prostate cancer cases in the US that year alone. Separately, prostate cancer statistics published in CA: A Cancer Journal for Clinicians put the lifetime risk at roughly 1 in 8 American men. And yet most cases are caught at an early, treatable stage when screening happens on schedule.

Is the digital rectal exam still necessary if my PSA is normal?

Possibly yes, especially if you’re at higher risk. A DRE can detect physical abnormalities in the prostate even when PSA is within normal range, so most urologists still recommend it as part of a complete evaluation.

What age can I stop getting screened?

For most men, routine screening wraps up around age 75, particularly when PSA is below 3 ng/mL and overall health isn’t excellent. Men with less than 10 years of estimated life expectancy are unlikely to benefit from continued screening. Your doctor should make that call with you, based on your individual picture.

Conclusion

Regular prostate screening saves lives. How often a man should get his prostate checked depends on his age, PSA history, family background, and ethnicity. For most men at average risk, screening every 2 to 4 years from age 50 to 69 is the current standard, with annual checks if PSA is elevated. Higher-risk men should start at 40 to 45 and screen more consistently. Research in CA: A Cancer Journal for Clinicians tracking prostate cancer in over 313,000 new diagnoses confirms that early detection, guided by these intervals, is the most effective tool men have for catching the disease at a treatable stage. This article is for informational purposes and is not a substitute for professional medical advice. Talk to your doctor about the right schedule for you.